Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise by Penna, Fabio et al.
ORIGINAL ARTICLE
Combined approach to counteract experimental cancer
cachexia: eicosapentaenoic acid and training exercise
Fabio Penna & Silvia Busquets & Fabrizio Pin & Miriam Toledo & Francesco M. Baccino &
Francisco J. López-Soriano & Paola Costelli & Josep M. Argilés
Received: 17 December 2010 /Accepted: 20 April 2011 /Published online: 11 May 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Background Cancer cachexia is a syndrome characterized
by loss of skeletal muscle protein, depletion of lipid stores,
anorexia, weakness, and perturbations of the hormonal
homeostasis. Despite several therapeutic approaches
described in the past, effective interventions countering
cancer cachexia are still lacking.
Methods The present work was aimed to verify the ability
of eicosapentaenoic acid (EPA) to prevent the muscle
depletion in Lewis lung carcinoma-bearing mice and to
test the ability of endurance exercise training to increase the
EPA effect.
Results EPA alone did not prevent the muscle loss induced
by tumor growth while the combination with exercise
induced a partial rescue of muscle strength and mass.
Moreover, the association of EPA and exercise reduced the
dramatic PAX-7 accumulation and stimulated the increase
of PCG-1 protein.
Conclusions Overall, the present data suggest that exercise
is an effective tool that should be added for combined
therapeutic approaches against cancer cachexia.
Keywords Experimental cancer cachexia.Training
exercise.Muscle wasting.Eicosapentaenoic acid
1 Introduction
Cancer patients frequently develop a condition of general
wasting known as cachexia. This is a multifactorial
syndrome that complicates patients’ management, increases
morbidity and mortality rates, reduces the tolerance to
antineoplastic therapies, and results in poor quality of life
[1]. Cachexia is characterized by muscle and fat wasting,
anemia, anorexia, and perturbations of the hormonal
homeostasis. The pathogenetic mechanisms underlying
cachexia are complex and only partially identified, thereby
effective therapeutic strategies are lacking.
Several therapeutic approaches have been proposed to
counteract cachexia. Among these are nutritional interven-
tions, frequently including omega-3 polyunsaturated fatty
acids (PUFA) [2], antioxidants [3], branched-chain amino
acids [4], agonists of the melanocortin receptor [5], ghrelin
[6], and anti-myostatin agents [7]. The omega-3 PUFAs
eicosapentaenoic acid (EPA) and docosahexaenoic acid have
been shown to suppress the production of proinflammatory
cytokines of several molecules deriving from the arachidonic
acid cascade and of acute-phase reactants such as C-reactive
protein (reviewed in [8, 9]). EPA administration to animals
bearing the MAC16 tumor improves body weight loss and
attenuates the catabolic effects of both lipid mobilizing factor
and proteolysis-inducing factor (see [10]). In particular, in the
MAC16 model system, EPA has been shown to inhibit the
activity of the ubiquitin–proteasome-dependent proteolysis,
thus reducing skeletal muscle wasting [11]. Finally, experi-
mental studies suggest that omega-3 PUFAs may impair both
tumor growth and metastatic spread, mainly by inducing
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DOI 10.1007/s13539-011-0028-4apoptotic cell death, reducing pro-angiogenic factors, and
inhibiting oncogene expression (reviewed in [10]). By
contrast, EPA proved ineffective in preventing cachexia in
rats bearing the AH-130 hepatoma [12].
Clinical trials performed in malnourished cancer patients
have shown that EPA administration improves body weight
and lean body mass, likely in force of its anti-inflammatory
properties [9, 13]. These observations, however, have not
been completely confirmed by a large multicenter study
performed on pancreatic cancer patients [14]. Finally, EPA
administration per se has been demonstrated to exert no
statistically significant benefit in the treatment of cancer
cachexia [15].
In addition to nutritional interventions, other therapeutic
strategies could effectively contribute to attenuate cancer-
related muscle wasting. In particular, exercise training has
been proposed as a suitable tool, in view of recent
observations, suggesting that decreased physical activity
plays a role in the onset of muscle atrophy in cancer
patients [16]. Indeed, exercise training stimulates the
increase of muscle mass and strength and might improve
cancer-associated skeletal muscle wasting by stimulating
anabolic pathways as well as by down-regulating the
activity of proinflammatory cytokines [17]. The molecular
events that follow an acute bout of resistance exercise have
been described by several studies (reviewed in [18]); by
contrast, little is known about the effect induced by
repeated exercise bouts.
The aim of the present study has been to investigate if
EPA effectiveness in the prevention of cancer-related
cachexia might be enhanced by the association with
endurance exercise training. The study has been performed
on a well-established model of cancer cachexia, namely
mice bearing the Lewis lung carcinoma (LLC). The results
obtained show that EPA administration to tumor hosts does
not modify the wasting process, while the association with
the exercise results in partial restoration of both muscle
mass and strength.
2 Materials and methods
All materials were supplied by Sigma (St. Louis, MO,
USA), unless differently specified.
2.1 Animals and experimental design
C57BL/6 mice weighing about 20 g (Interfauna, Barcelona,
Spain) were maintained on a regular dark–light cycle (light from
08:00 to 20:00) with free access to food and water during the
whole experimental period. They were cared for in compliance
with the Policy on Humane Care and Use of Laboratory
Animals elaborated by the National Institues of Health. The
experimental protocol has been approved by the Bioethical
Committee of the University of Barcelona. All animal
manipulations were made in accordance with the European
Community guidelines for the use of laboratory animals.
Animals were randomized and divided into two groups,
namely controls (C, n=15) and tumor bearers (LLC, n=24).
Tumor-bearing mice were inoculated intramuscularly with
5×10
5 LLC cells. Both controls and LLC where divided
into three sub-groups (n=5 for C, n=8 for LLC): untreated,
treated with EPA, and treated with EPA and submitted to
endurance exercise. EPA-treated groups received daily
intragastric administration of 0.5 g/kg EPA in corn oil
starting from the fourth day of tumor growth (the same dose
used by [19]) while untreated groups received vehicle
alone. As for the exercise protocol, mice were exercised on
a Panlab/Harvard-Apparatus treadmill (Barcelona, Spain).
Briefly, mice were made to get used to the treadmill for
5 days before tumor injection (starting from 6 m/min for
15 min, increasing speed and time daily until reaching 60–
70% of maximum oxygen consumption, corresponding to
14 m/min for 45 min). VO2 max (using a Panlab/Harvard-
Apparatus Oxylet System, Barcelona, Spain) was measured
after the 5 days adaptation period, and the exercise
conditions were maintained constant for all the experimen-
tal period. Mice were exercised 5 days/week starting the
day after tumor implantation. A schematic drawing of the
experimental design including the time points of the
different measures in the animals is presented in Fig. 1.
Animal weight and food intake were recorded daily.
Tumor-bearing mice were sacrificed under anesthesia
14 days after tumor injection. Several muscle ant tissues
were rapidly excised, weighed, frozen in isopentane cooled
with liquid nitrogen, and stored at −80°C for further
analysis.
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VO2max test (EX group), grip 
test (all groups), tumor 
injection (LLC groups)
EPA administration (0.5 g/kg)
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grip test, sacrifice
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Experimental groups:
- Controls (C; n=5)
- Exercise (EX; n=5) 
- EPA + exercise (EPA EX; n=5)
- LLC hosts (LLC; n=8) 
- LLC + exercise (LLC EX; n=8)
- LLC + EPA + exercise ( LLC 
EPA EX; n=8)
Fig. 1 Schematic drawing of the experimental design including the
time points of the different measurements performed in the mice.
Group size is presented in parentheses
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Total physical activity (IR ACTIMETER System and
ACTITRAK software from PANLAB, Barcelona) was
determined during the last 24 h before the sacrifice of the
animals in control and tumor-bearing animals using activity
sensors that translate individual changes in the infrared
pattern caused by movements of the animals into arbitrary
activity counts [20]. For the measurements, animals
remained in their home cage. A frame containing an
infrared beam system was placed on the outside of the
cage; this minimized stress to the animals.
2.3 Grip force assessment
Skeletal muscular strength in mice was quantified by the
grip-strength test [21, 22]. The grip-strength device (Panlab/
Harvard Apparatus, Spain) comprised a triangular pull bar
connected to an isometric force transducer (dynamometer).
Basically, the grip-strength meter was positioned horizontally,
and the mice are held by the tail and lowered towards the
device. The animals are allowed to grasp the triangular pull
bar and were then pulled backwards in the horizontal plane.
The force applied to the bar just before it lost grip was
recorded as the peak tension. At least three measurements
were taken per mouse on both baseline and test days, and the
results were averaged for analysis.
2.4 ELISA
γ-Interferon (IFN) serum levels were detected by a commer-
cially available mouse ELISA kit, used according to the
manufacturer instructions (Bender MedSystems, Vienna,
Austria). Serum from each animal (50 μl) was assayed in
duplicate. Quantitative calibration was obtained performing a
standard curve with recombinant mouse γ-IFN.
2.5 Western blotting
Samples from gastrocnemius muscle (about 50 mg) were
homogenized in 10 mM 4-(2-hydroxyethyl)-1 piperazineetha-
nesulfonic acid (HEPES), pH 7.5, containing 10 mM MgCl2,
5 mM KCl, 0.1 mM ethylenediaminetetraacetic acid (EDTA),
and 0.1% Triton X-100, with freshly added protease and
phosphatase inhibitor cocktails, centrifuged at 3,000×g for
5 min at 4°C and the supernatant collected as cytosolic
extract. The pellet was resuspended in 20 mM HEPES,
pH 7.9, containing 1.5 mM MgCl2,5 0 0m MN a C l ,0 . 2m M
EDTA, and 25% glycerol, with freshly added protease and
phosphatase inhibitor cocktails, incubated on ice for 30 min,
centrifuged at 3,000×g for 5 min at 4°C, and the supernatant
collected as nuclear extract. Protein concentration was assayed
by the method of Lowry [23] using bovine serum albumine as
working standard. Equal amounts of protein (30 μg) were
heat-denaturated in sample-loading buffer (50 mM Tris–HCl,
pH 6.8, 100 mM dithiothreitol, 2% Sodium Dodecyl Sulphate
(SDS), 0.1% bromophenol blue, 10% glycerol), resolved by
SDS-PolyAcrylamide Gel Electrophoresis and transferred to
nitrocellulose membranes (Bio-Rad, Hercules, CA, USA).
The filters were blocked with Tris-buffered saline containing
0.05% Tween and 5% non-fat dry milk and then incubated
overnight with antibodies directed against: PGC-1 (Millipore,
Billerica, MA, USA), atrogin-1 (ECM Biosciences, Versailles,
KY, USA), and Pax7 (developed by Atsushi Kawakami,
obtained from the Developmental Studies Hybridoma Bank,
University of Iowa). Peroxidase-conjugated IgG (Bio-Rad,
Hercules, CA, USA) were used as secondary antibodies.
Membrane-bound immune complexes were detected by an
enhanced chemiluminescence system (Santa Cruz Biotechno-
logy, USA) on a photon-sensitive film (Hyperfilm ECL, GE
Healthcare, Milano, Italy). Protein loading was normalized
according to tubulin (Sigma, St. Louis, MO, USA) expression.
Quantification of the bands was performed by densitometric
analysis using specific software (TotalLab, NonLinear
Dynamics, Newcastle upon Tyne, UK).
2.6 Proteasome enzymatic activity
Proteasome activity in the gastrocnemius was determined by
cleavage of specific fluorogenic substrates. The tissue was
homogenized in 20 mM Tris–HCl, pH 7.2, containing 0.1 mM
EDTA, 1 mM 2-mercaptoethanol, 5 mM ATP, 20% glycerol,
and0.04%(v/v) Nonidet P-40. Muscle homogenates were then
centrifuged at 13,000×g for 15 min at 4°C. The supernatant
was collected and protein concentration determined as de-
scribed above. Aliquots of 50 μg protein were then incubated
for 60 min at 37°C in the presence of succinyl-Leu-Leu-Val-
Tyr-7-AMC (LLVY). The incubation buffer for the evaluation
of the enzymatic activity was 50 mM HEPES, pH 8.0,
containing 5 mM ethylene glycol tetraacetic acid. Fluorescence
was read with a spectrofluorometer (380 nm excitation, 460 nm
emission; Perkin–Elmer, Norwalk, CT, USA). The activity was
calculated by using free AMC as working standard.
2.7 Data analysis and presentation
All results were expressed as mean±SD. Significance of the
differences was evaluated by analysis of variance followed
by Tukey’s test.
3 Results
In comparison with control animals, mice bearing the LLC
tumor markedly reduce their cumulative food intake; daily
administration of EPA (0.5 g/kg; this dose effectively
J Cachexia Sarcopenia Muscle (2011) 2:95–104 97prevents cachexia in MAC16-bearing mice; see [19]) does
not modify the decrease in food intake that is partially
corrected by treatment with EPA and exercise (C=64.8 g,
LLC=50.0 g, LLC EPA EX=54.6 g; Fig. 2a).
In a voluntary grip-strength test, LLC-bearing mice develop
a force 30% lower than control animals (C ¼ 1:19   0:05 N,
LLC ¼ 0:84   0:16N; Fig. 2b). EPA administration does not
prevent force reduction in LLC hosts, whereas its combination
with exercise results in a limited but significant recovery
(LLC EPA EX ¼ 0:96   0:21 N, p=0.04 vs LLC). Muscle
strength in control groups is not affected by EPA or EPA +
exercise (Fig. 2b).
Analysis of the animal behavior, evaluated for 24 h in a
continuous recording activity cage, shows a dramatic fall in
the total activity of LLC-bearing mice (Fig. 3a); both fast
and slow movements are reduced, the former more
markedly than the latter (Fig. 3b). Despite the protection
exerted against muscle weight loss, the combination of EPA
and exercise reveals unable to prevent the decrease of both
total andspecificactivityinducedbyLLCgrowth(Fig.3a, b).
Activity (total or specific) in control groups is qualitatively
comparable to the corresponding LLC hosts (Fig. 3a, b).
Tumor growth in LLC-bearing mice is associated with loss
of skeletal musclemass(Fig. 4). Consistently with the loss of
muscle strength, 14 days after tumor injection, the weight of
both gastrocnemius and tibialis muscles is about 70% of
controls (gastrocnemius, C ¼ 570   32, LLC ¼ 417   30;
tibialis: C ¼ 163   13, LLC ¼ 118   14 mg=100g initial
body weight). By contrast, the heart is only slightly affected
and loses about 7% of control weight (C ¼ 466   25,
LLC ¼ 434   31mg=100g i:b:w:). EPA treatment does not
counteract muscle atrophy in LLC-bearing mice (Fig. 4).
When EPA treatment is associated with training exercise,
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
C EPA EPA EX LLC LLC EPA LLC EPA 
EX
N
grip strength
* *
$
0
10
20
30
40
50
60
70
C EPA EPA EX LLC LLC EPA LLC EPA 
EX
g
cumulative food intake
b
a
Fig. 2 Cumulative food intake (a) and voluntary grasping strength (b)
in control (C) and LLC-bearing mice (LLC). Both groups were
subdivided in untreated, EPA-treated (EPA), and EPA-treated plus
exercised (EPA EX, see Section 2). Data (means±SD) expressed as
grams (g) for food intake and Newtons (N) for strength. Significance
of the differences: *p<0.05 vs C;
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(LLCEPAEX¼ 455   24mg=100g i:b:w:, p =0.02 vs
LLC; Fig. 4).
Among the other tissues analyzed, liver weight is
unchanged in all experimental groups, while spleen mass
increases about fourfold in all LLC-bearing animals,
independently from the treatment (Fig. 5). The systemic
inflammation, suggested by the spleen hypetrophy, is
confirmed by the increased circulating levels of γ-IFN
(C ¼ 46   30, LLC ¼ 188   127pg=ml). Similar to the
spleen weight, EPA administration, alone or in combination
with the exercise, does not prevent the γ-IFN raise
(LLCEPA ¼ 194   141, LLCEPAEX ¼ 196   118pg=ml ).
Finally, white perirenal adipose tissue virtually disappears in
both untreated and treated LLC hosts (Fig. 5).
Tumor mass remains comparable between untreated and
EPA-treated mice (Fig. 5). However, when EPA is coupled
to exercise, a small but statistically significant tumor
reduction in size can be observed (LLC ¼ 5:42   0:46,
LLCEPAEX ¼ 4:42   0:92g, p=0.013; Fig. 5).
Muscle wasting in cancer cachexia mainly relies on a
hypercatabolic response in which the ubiquitin–proteasome
system seems to play a major role [24]. Atrogin-1 is a
muscle-specific Ub-protein ligase (E3) critically involved in
the enhancement of proteolysis [25], overexpressed in
several conditions associated with muscle atrophy [26]. In
apparent contrast with these reports, however, the present
study shows that atrogin-1 protein expression in the
gastrocnemius is comparable between untreated and treated
LLC-bearing mice (Fig. 6a). This observation suggests that
atrogin-1 expression might not the best marker of muscle
proteolysis, as recently proposed [27], and/or that other
catabolic systems likely contribute to muscle wasting in
LLC hosts. The latter hypothesis is supported by the
observation that proteasome chymotrypsin-like activity
does not increase in the skeletal muscle of TB mice, at
least at the time point considered in the present study
(Fig. 6b).
Protein hypercatabolism apart, muscle wasting could
also be associated with alterations in the myogenic process.
Impaired myogenesis has been recently suggested to
contribute to the onset of muscle wasting in experimental
cancer cachexia [28]. Pax7 protein levels, measured in the
nuclear extracts, markedly increase in LLC-bearing mice
(Fig. 7); such increase is prevented in part by the
combination EPA + exercise.
Previous observations have shown that the levels of
the peroxisome proliferator-activated receptor γ (PPARγ)
coactivator1 (PGC-1),a factorthatstimulatesthe switchfrom
glycolytictooxidative fibers,is reducedindifferentmodelsof
skeletal muscle atrophy, including cancer cachexia [29, 30].
In the present experimental setting, however, PGC-1 protein
levels do not decrease in tumor-bearing mice with respect to
controls, while they are increased by EPA administration
coupled to exercise (Fig. 7).
4 Discussion
In the present study, EPA, a widely studied PUFA, was
combined with exercise training in order to enhance its
hypothetical effectiveness in the prevention of experimental
cancer cachexia.
Several studies proposed PUFA supplementation as an
effective tool against different pathologies, including sepsis,
coronary artery disease, asthma, inflammatory bowel
disease, and cancer (reviewed in [31]). The results obtained
in the present study showed that EPA administration to
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and EPA-treated plus exercised
(EPA EX, see Section 2). Data
(means±SD) expressed as
percentages of controls.
Significance of the differences:
***p<0.001 vs C;
$p<0.05 vs LLC
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tumor-induced muscle wasting. This is in contrast with a
number of reports demonstrating a protective action of EPA
in mice bearing the MAC16 tumor [19, 32–34]. The
discrepancy between the present results on LLC-bearing
mice and those reported in the MAC16 hosts could reside
in the intrinsic differences that characterize these experi-
mental models. In this regard, studies performed on rats
bearing the AH-130 hepatoma [12] and clinical trials
involving cachectic patients affected by gastrointestinal or
lung cancer [15] reported the ineffectiveness of EPA
supplementation. Finally, another fatty acid with antinflam-
matory properties, the c9t11 conjugated linoleic acid, did
not improve muscle depletion in Colon26-bearing mice
[35]. These considerations apart, however, the possibility
that the dose of EPA adopted in the present study might be
insufficient to elicit changes should be taken into account.
Actually, there is no general consensus about the optimal
EPA dosage needed to obtain pharmacological effects. As
an example, 110 mg/day was required to revert insulin
resistance in obese mice [36] while 0.49 mg/day were used
in another study [37]; in both reports, EPA supplementation
was effective, despite the very different range (200-folds).
The doses above are 11-fold higher and 20-fold lower,
respectively, than the one used in the present study (0.5 g/kg
body weight, corresponding to 10 mg/day). Choosing EPA
dosage, particular attention has been given to look for a
therapeutic dose unable tointerfere with tumor growth. Inthis
regard, 0.5 g/kg was shown to prevent muscle wasting in
MAC16-bearing mice [19] while 2.5 g/kg also resulted in
tumor growth inhibition [32], rendering quite impossible to
enucleate muscle-specific effects of the treatment.
In the clinical practice, exploitation of the potential
benefits of PUFA administration is still largely limited by
the poor knowledge of their mechanisms of action. In this
regard, PUFA therapeutic effects are commonly accepted to
rely on their antinflammatory actions, exerted by reducing
the production of inflammatory cytokines, such as tumor
necrosis factor alpha, interleukin-1, and interleukin-6 [31].
In the present study, spleen weight, an indirect indicator of
the systemic inflammatory state, was increased by fourfold
in LLC-bearing mice and not modified by EPA adminis-
tration, suggesting that tumor-induced systemic inflamma-
tion was only marginally affected by the treatment. This
hypothesis is further supported by the observation that
circulating levels of γ-IFN, the mediator mainly involved in
the pathogenesis of cachexia in LLC-bearing mice [38],
increased in tumor hosts and were not modified by EPA. In
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immune response and proinflammatory cytokine production
by PUFA may not be a general finding [39].
Summarizing, treatment with EPA alone does not appear
suitable to prevent cancer cachexia, despite being a good
candidate for the treatment of other experimental wasting
conditions such as diabetes [40] and arthritis [41]. The
different effectiveness of EPA in counteracting the various
types of muscle atrophies may depend on the underlying
pathogenetic mechanisms. As an example, the redox
imbalance differently contributes to muscle depletion in
diabetes and in cancer cachexia, as shown by the observation
that antioxidant treatment markedly prevented muscle
atrophy in the former while only partially in the latter [42].
Several reports suggested training exercise as a strategy to
mitigate muscle wasting in chronic pathological conditions
(reviewed in [17]). The underlying mechanisms accounting
for these protective effects are still not entirely clear. Exercise
training was proposed to stimulate mitochondrial biogenesis
to increase muscle protein synthesis rate and to attenuate
protein hypercatabolism [17]. Moreover, resistance training
proved effective in restoring lean body mass and function in
patients with rheumatoid arthritis-related cachexia, stimulating
the enhancement of muscle IGF-1 levels [43].
Unfortunately, the usefulness of exercise in cancer
patients received little attention in the past. The currently
available data provide preliminary evidence that exercise
training is a well-tolerated and safe complementary therapy
that can mitigate several common treatment-related side
effects, including breath shortness and pain [44]. A
common feature of cancer patient is fatigue. In this regard,
a large body of evidence supports the beneficial effect of
exercise training in counteracting fatigue [45]. In the
present work, we provide the first evidence that endurance
training coupled to EPA administration partially prevented
the loss of muscle mass and strength in tumor-bearing mice.
The improvement of muscle depletion was associated with
a small but significant decline in tumor burden in exercised,
EPA-treated mice, while no differences were seen in mice
treated with EPA alone. This observation is consistent with
previous data showing that anaerobic resistance training in
Waker-256-bearing rats strongly reduced tumor growth [46]
while swimming exercise attenuated colon carcinogenesis
in the rat [47]. On the contrary, however, another study
reported that tumorigenesis increased in p53-deficient mice
exercised with a treadmill protocol similar to the one used
in the present study [48]. Exercise-induced suppression of
tumor growth was hypothesized to depend on modulations
of inflammation [49, 50]. However, both spleen hypertro-
phy and γ-IFN circulating levels in LLC-bearing mice were
not affected by the combination of exercise and EPA,
suggesting that, at least in the present experimental
conditions, the systemic inflammatory response is not
involved in the inhibition of LLC growth. On the whole,
the effect of exercise training on tumor growth is still
debated, and on the other side, the modulation of molecular
pathways induced by the exercise plus EPA in the muscle
suggests that the small reduction of tumor growth has a
limited relevance in the anti-cachectic effects here reported.
EPA did not prevent muscle wasting when administered
alone but was able to modulate both muscle mass and
strength when coupled to exercise. From this point of view,
the effectiveness of EPA + exercise could primarily result
from exercise alone. Although this is a relevant point, such
possibility was discarded in the present study, since
previous results obtained on Colon26-bearing mice showed
that the same exercise protocol adopted for the LLC hosts
not only did not prevent, but even worsened tumor-induced
muscle wasting (Electronic Supplementary Fig. S1). Similar
results were obtained when Colon26-bearing mice were
exposed to an 8-week exercise protocol, thus excluding that
the lack of protection could depend on exercise duration
and suggesting the adoption of a combined approach.
The association of EPA with exercise in LLC-bearing
mice resulted in attenuation of tumor-induced anorexia,
associated with unchanged voluntary (extra-exercise) activity
that was close to untreated LLC bearers. In this regard,
physical conditions in LLC hosts might be improved by
exercise and EPA, leading tumor bearers to cope with the
increased energy requirements by enhancing food intake
rather than by further increasing the resting period, already
significantly higher than that observed in treated, exercised
controls. On the other side, food intake remained comparable
between control groups (EPA-treated, exercised, and EPA
untreated, sedentary). Such a discrepancy between trained,
EPA-treated controls, and LLC hosts might reflect a different
response to exercise. Indeed, voluntary activity was lower in
trained than in sedentary controls, suggesting that healthy
animals managed the enhanced energy requirement by simply
recovering after exercise, without modifying food intake. On
the contrary, in LLC hosts, resting time, already markedly
higher than in controls, did not further increase after training.
Also taking into consideration that cachexia can be associated
withincreasedrestingenergyexpenditure [10], modulation of
food intake might be the mechanism by which trained
animals manage the enhanced energy requirement.
Apart from reduced food intake that was shown to play a
limited role in cancer-associated muscle depletion [26, 35],
other tumor-induced metabolic alterations could be targeted
by the exercise. Indeed, endurance exercise was shown to
induce the restoration of lipid metabolism in tumor-bearing
rats [51] while resistance exercise modulates both protein
synthesis anddegradationrates in normalor wastingconditions
(reviewed by [52]). Finally, resistance training increased
muscle mitochondrial biogenesis in patients affected by
chronic kidney disease [53]. In the present work, endurance
J Cachexia Sarcopenia Muscle (2011) 2:95–104 101training in association with EPA induced the increase of PGC-
1 protein levels in LLC-bearing mice, possibly stimulating
mitochondrial biogenesis and a shift from fast- to slow-twitch
oxidative fibers, less susceptible to atrophy.
Recent data showed that muscle wasting in Colon26-
bearing mice was associated with reduced myogenin
levels and increased expression of Pax7, an inhibitor of
the myogenic program [54], suggesting the occurrence of
impaired myogenesis [28]. The results obtained in the
present work confirmed the enhancement of Pax7 expres-
sion also in the skeletal muscle of LLC-bearing mice; this
might suggest an increased satellite cell proliferation or
their impaired differentiation. Loss of myonuclei, previ-
ously reported in Colon26-bearing mice [55], could lead to
enhancement of satellite cell proliferation; such increase,
however, could be vanished by the inability to complete
the myogenic program, contributing to the atrophic
phenotype. The present work provides the first evidence
that endurance exercise, even for the short period adopted
for this study, in association with EPA, partially prevented
muscle Pax7 increase in LLC hosts; this observation
suggests that satellite cells might proceed into the
myogenic program, thus partially explaining the protection
exerted by such experimental protocol against LLC-
induced muscle wasting.
In conclusion, the results shown in the present study
demonstrate that the association between EPA and endur-
ance exercise improved muscle wasting in LLC hosts,
mainly by modulating some of the molecular pathways
involved in the pathogenesis of muscle depletion, encour-
aging the inclusion of training exercise in the multi-
disciplinary therapeutic approach that should be adopted
to prevent cancer cachexia.
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